GlassScriptPhysician profile
Scott L Massien
NPI 1093811879
$1,076.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $122 · 2021: $47.17 · 2022: $27.50 · 2024: $65.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.48 | 2019-2024 | |
| Pfizer INC. | $138.55 | 2019-2020 | |
| Amarin Pharma, INC. | $121.90 | 2019-2020 | |
| Novo Nordisk INC | $116.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $93.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.42 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.47 | 2019 | |
| Amgen INC. | $60.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $57.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.77 | 2019 | |
| Astellas Pharma US INC | $31.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.37 | 2019 | |
| Abbott Laboratories | $23.67 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.75 | 2019 | |
| Merck Sharp & Dohme LLC | $14.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.39 | 2019 | |
| Allergan, INC. | $13.17 | 2019 | |
| Hikma Pharmaceuticals USA | $12.78 | 2019 | |
| Kyowa Kirin, INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Massien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.